Matthew Brams, MD
Psychiatry · Houston, TXNPI 1639187263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,263,566 of the $1,504,805 with a category attached, or 84.0%. 31 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 50.8% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,685 payments — averaging $893.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$765K
- Teva Pharmaceuticals USA, Inc.$355K
- Vanda Pharmaceuticals Inc.$105K
- Neurocrine Biosciences, Inc.$52K
- Sunovion Pharmaceuticals Inc.$50K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44K
- plus $134K from 25 others
Across 30 payments — averaging $50,132 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adlon Therapeutics L.p.$1.2M
- Purdue Pharma L.p.$259K
- Supernus Pharmaceuticals, Inc.$12K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- E.r. Squibb & Sons, L.L.C.$4K
- AbbVie$155
What the payments were for
- Consulting fees$80,0975%
- Speaking & faculty fees$1,263,56684%
- Travel & lodging$121,7248%
- Food & beverage$39,3973%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 780 | $764,835 |
| Teva Pharmaceuticals USA, Inc. | 276 | $354,725 |
| Vanda Pharmaceuticals Inc. | 100 | $105,143 |
| Neurocrine Biosciences, Inc. | 86 | $52,085 |
| Sunovion Pharmaceuticals Inc. | 68 | $49,656 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $44,000 |
| E.r. Squibb & Sons, L.L.C. | 43 | $38,767 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 36 | $36,533 |
| Tris Pharma Inc | 58 | $23,925 |
| Alkermes, Inc. | 6 | $7,913 |
| Livanova USA, Inc. | 4 | $6,674 |
| Ironshore Pharmaceuticals Inc. | 15 | $5,669 |
| Lundbeck LLC | 10 | $4,702 |
| Johnson & Johnson | 21 | $3,441 |
| Corium, LLC | 15 | $2,179 |
| Supernus Pharmaceuticals, Inc. | 7 | $1,623 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $604 |
| AbbVie(2 entities) | 26 | $549 |
| Neos Therapeutics, LP | 10 | $511 |
| Axsome Therapeutics, Inc. | 3 | $287 |
| Bausch Health US, LLC | 12 | $249 |
| Merck | 9 | $146 |
| Neuronetics, Inc. | 3 | $143 |
| Indivior Inc. | 6 | $143 |
| Jazz Pharmaceuticals Inc. | 7 | $124 |
| Noven Therapeutics, LLC | 2 | $44 |
| Adlon Therapeutics L.p. | 2 | $35 |
| Almatica Pharma LLC | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$386,872
- REXULTI$371,006
- AUSTEDO$184,087
- ABILIFY ASIMTUFII$127,674
- Austedo XR$126,265
- Fanapt$103,985
- INGREZZA$50,949
- LATUDA$48,938
- CAPLYTA$43,368
- UZEDY$41,533
- COBENFY$24,387
- Dyanavel XR$22,397
- ABILIFY MYCITE$14,570
- Quillivant$6,699
- VNS Therapy Symmetry Model 8103 Generator$6,674
- Quillichew ER$6,270
- JORNAY PM$5,400
- SPRAVATO$2,987
- ADLARITY$1,200
- Azstarys$646
How this compares
$1,504,805 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $125,089 |
| RexultiBrexpiprazole | 35 | $54,658 |
| Abilify MaintenaAripiprazole | 12 | $38,377 |
| VraylarCariprazine Hcl | 14 | $23,304 |
| LatudaLurasidone Hcl | 12 | $16,175 |
| Risperdal ConstaRisperidone Microspheres | 13 | $15,718 |
| Lisdexamfetamine Dimesylate | 75 | $13,540 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $13,277 |
| AmbienZolpidem Tartrate | 13 | $7,794 |
| LexaproEscitalopram Oxalate | 11 | $5,076 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 107 | $4,290 |
| Alprazolam | 326 | $2,782 |
| Ziprasidone Hcl | 41 | $2,780 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 66 | $2,583 |
| Lurasidone Hcl | 20 | $2,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $354,725 | $125,08912 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $764,835 | $93,03547 claims |
| AbbVieVraylar, Lexapro | $549 | $28,38025 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $49,656 | $16,17512 claims |
| Johnson & JohnsonRisperdal Consta | $3,441 | $15,71813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $604 | $13,27728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.